Abstract
Cathinone-derived designer drugs have recently grown to be popular as drugs of abuse. 3,4-Dimethylmethcathinone (DMMC) has recently been abused as one of the alternatives to controlled cathinones. In the present study, DMMC and its major metabolites, 3,4-dimethylcathinone (DMC), 1-(3,4-dimethylphenyl)-2-methylaminopropan-1-ol (β-OH-DMMC, diastereomers), and 2-amino-1-(3,4-dimethylphenyl)propan-1-ol (β-OH-DMC, diastereomers), have been identified and quantified in a DMMC user’s urine by gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry using newly synthesized authentic standards. Other putative metabolites including oxidative metabolites of the xylyl group and conjugated metabolites have also been detected in urine. The identified and putative phase I metabolites indicated that the metabolic pathways of DMMC include its reduction of the ketone group to the corresponding alcohols, N-demethylation to the primary amine, oxidation of the xylyl group to the corresponding alcohol and carboxylate forms, and combination of these steps. Concentrations of the identified metabolites were found to increase slightly after enzymatic hydrolysis, suggesting that these compounds are partially metabolized to the respective conjugates.
Similar content being viewed by others
References
Jane MP, Lewis SN (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42
Ammann D, McLaren JM, Gerostamoulos D, Beyer J (2012) Detection and quantification of new designer drugs in human blood: part 2—designer cathinones. J Anal Toxicol 36:381–389
Karila L, Petit A, Cottencin O, Coscas S, Reynaud M (2012) Synthetic drugs: the new low-cost landscape of drugs. Rev Prat 62:664–666
Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436–441
Namera A, Nakamoto A, Saito T, Nagao M (2011) Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review. Forensic Toxicol 29:1–24
Locos O, Reynolds D (2012) The characterization of 3,4-dimethylmethcathinone (3,4-DMMC). J Forensic Sci. doi:10.1111/j.1556-4029.2012.02142.x
James D, Adams RD, Spears R, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SH (2011) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 28:686–689
Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F (2011) Mephedrone, new kid for the chop? Addiction 106:154–161
Winstock AR, Mitcheson LR, Marsden J (2010) Mephedrone: still available and twice the price. Lancet 376:1537
Carhart-Harris RL, King LA, Nutt DJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend 118:19–22
Sogawa C, Sogawa N, Ohyama K, Kikura-Hanajiri R, Goda Y, Sora I, Kitayama S (2011) Methylone and monoamine transporters: correlation with toxicity. Curr Neuropharmacol 9:58–62
Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63–69
Servin A, Fauquet JP, Jacquot C, Rapin JR (1978) Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 27:1693–1694
Bonnet JJ, Protais P, Chagraoui A, Costentin J (1986) High-affinity [3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. Eur J Pharmacol 126:211–222
Vaugeois JM, Bonnet JJ, Costentin J (1992) In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783. Eur J Pharmacol 210:77–84
Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011) Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol. doi:10.1111/j.1476-5381.2011.01499.x
Gregory CH, Katy MW, Lisa MM, Pei WC, Jonathan DE, Scott CA, David MA, Paula LVB, Christopher LG, Kevin MC, Amanda JH, James WG, Diana GW, Glen RH, Annette EF (2011) 4-Methylmethcathinone (mephedrone): Neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. doi:10.1124/jpet.111.184119
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203
Zaitsu K, Katagi M, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2011) Recently abused β-keto derivates of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxciological analysis. Forensic Toxicol 29:73–84
Zaitsu K, Katagi M, Kamata HT, Kamata T, Shima N, Miki A, Tsuchihashi H, Mori Y (2009) Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188:131–139
Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H (2006) Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36:709–723
Kamata HT, Shima N, Zaitsu K, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H (2007) Simultaneous analysis of new designer drug, methylone, and its metabolites in urine by gas chromatography-mass spectrometry and liquid chromatography-electrospray ionization mass spectrometry. Jpn J Forensic Sci Tech 12:97–106
Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233
Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24:2706–2714
Meyer MR, Du P, Schuster F, Maurer HH (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high resolution MS and its detectability in urine by GC–MS. J Mass Spectrom 45:1426–1442
Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 796:253–266
Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952–964
Meyer MR, Vollmar C, Schwaninger AE, Wolf EU, Maurer HH (2012) New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC–MS and LC–high resolution MS and their detectability in urine. J Mass Spectrom 47:253–262
Mueller DM, Rentsch KM (2012) Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC–MS(n), and metabolism of 11 cathinones. Anal Bioanal Chem 402:2141–2151
Pawlik E, Plässer G, Mahler H, Daldrup T (2011) Studies on the phase I metabolism of the new designer drug 3-fluoromethcathinone using rabbit liver slices. Int J Legal Med. doi:10.1007/s00414-011-0601-6
Archer RP (2009) Fluoromethcathinone, a new substance of abuse. Forensic Sci Int 185:10–20
Pizarro N, de la Torre R, Farré M, Segura J, Llebaria A, Joglar J (2002) Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites. Bioorg Med Chem 10:1085–1092
Morita M, Ando H (1983) Analysis of methamphetamine and its metabolites in urine from a habitual user of the stimulant. Eisei Kagaku 29:318–322 (in Japanese)
Brenneisen R, Geisshüsler S, Schorno X (1986) Metabolism of cathinone to (−)-norephedrine and (−)-norpseudoephedrine. J Pharm Pharmacol 38:298–300
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shima, N., Katagi, M., Kamata, H. et al. Urinary excretion and metabolism of the newly encountered designer drug 3,4-dimethylmethcathinone in humans. Forensic Toxicol 31, 101–112 (2013). https://doi.org/10.1007/s11419-012-0172-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11419-012-0172-3